<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03816059</url>
  </required_header>
  <id_info>
    <org_study_id>20190104</org_study_id>
    <nct_id>NCT03816059</nct_id>
  </id_info>
  <brief_title>Respiratory Virus Infections in Acutely Hospitalized Adult Patients With Pulmonary and Extrapulmonary Complications</brief_title>
  <official_title>Respiratory Virus Infections in Acutely Hospitalized Adult Patients With Pulmonary and Extrapulmonary Complications</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Hong Kong</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Respiratory virus infections are one of the major causes of hospitalizations, and outbreaks&#xD;
      of respiratory virus infection have led to severe economic loss. In addition to pulmonary&#xD;
      complications, respiratory viruses can also lead to non-pulmonary complications.&#xD;
&#xD;
      However, many previous studies on the complications of respiratory viruses are retrospective&#xD;
      in nature, and therefore many patients with respiratory virus infection may not be tested.&#xD;
      Furthermore, these studies did not take into account that respiratory viruses can be found in&#xD;
      some asymptomatic individuals. The aim of this study is to capture the burden of respiratory&#xD;
      viruses in patients with acute pulmonary and extrapulmonary complications. We will recruit&#xD;
      patients admitted to our hospital with acute coronary syndrome, stroke and exacerbation of&#xD;
      underlying lung diseases. We will collect saliva from these patients and test for respiratory&#xD;
      viruses. As controls, we will recruit asymptomatic patients at the out-patient clinic for&#xD;
      follow up of chronic heart, lung or neurological diseases.&#xD;
&#xD;
      We anticipate that this study will greatly enhance our understanding of the epidemiology of&#xD;
      respiratory viruses in acutely hospitalized patients. Our findings will be important for&#xD;
      clinicians, public health practitioners and scientists.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Respiratory viruses cause severe infections, and contribute to a substantial number of&#xD;
      hospitalizations, admission to intensive care units and deaths. Many hospitalizations due to&#xD;
      respiratory virus infection are related to pneumonia or exacerbation of chronic lung disease.&#xD;
      In addition, many hospitalizations are related to extrapulmonary complications, such as acute&#xD;
      coronary syndrome or stroke.&#xD;
&#xD;
      Previous studies have reported the incidence of respiratory viruses among patients with&#xD;
      pulmonary complications, or the association of respiratory viruses with acute coronary&#xD;
      syndrome or stroke. However, there are several problems associated with these studies. First,&#xD;
      many of these studies are retrospective in nature, and therefore testing was only performed&#xD;
      in selected patients with respiratory symptoms. Hence, many patients without respiratory&#xD;
      symptoms were not recruited. Second, respiratory virus can be detected in some asymptomatic&#xD;
      individuals. Therefore, the presence of respiratory virus may be an incidental finding rather&#xD;
      than the cause of the complication. Third, many studies only focus on a few respiratory&#xD;
      viruses, especially on influenza virus.&#xD;
&#xD;
      This study aims to address these issues. The investigators propose to conduct a prospective&#xD;
      cohort study. The investigators will recruit hospitalized adult patients with exacerbation of&#xD;
      underlying lung disease, acute coronary syndrome or stroke. As controls, the investigators&#xD;
      will recruit outpatients follow-up for chronic heart disease, chronic lung disease or&#xD;
      neurological conditions. The investigators will collect saliva from study participants and&#xD;
      perform respiratory virus testing using a multiplex PCR panel. Previous studies have shown&#xD;
      that there is a high concordance between results from respiratory virus testing on saliva and&#xD;
      nasopharyngeal specimens. The investigators will also use a standardized questionnaire to&#xD;
      collect information regarding symptoms.&#xD;
&#xD;
      This study will provide accurate data on the epidemiology of respiratory viruses in pulmonary&#xD;
      and extrapulmonary complications.These data are important for clinicians, public health&#xD;
      practitioners and scientists.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">February 12, 2019</start_date>
  <completion_date type="Anticipated">April 20, 2020</completion_date>
  <primary_completion_date type="Actual">June 30, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of respiratory viruses</measure>
    <time_frame>2 days</time_frame>
    <description>Incidence of respiratory viruses</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>1 month</time_frame>
    <description>Length of hospital stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay in general medical ward</measure>
    <time_frame>1 month</time_frame>
    <description>Length of stay in general medical ward</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay in high dependency unit</measure>
    <time_frame>1 month</time_frame>
    <description>Length of stay in high dependency unit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay in intensive care unit</measure>
    <time_frame>1 month</time_frame>
    <description>Length of stay in intensive care unit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients requiring oxygen supplementation</measure>
    <time_frame>1 month</time_frame>
    <description>Proportion of patients requiring oxygen supplementation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients requiring positive pressure ventilation</measure>
    <time_frame>1 month</time_frame>
    <description>Proportion of patients requiring positive pressure ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients requiring intubation</measure>
    <time_frame>1 month</time_frame>
    <description>Proportion of patients requiring intubation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients admitted to intensive care unit</measure>
    <time_frame>1 month</time_frame>
    <description>Proportion of patients admitted to intensive care unit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients admitted to coronary care unit</measure>
    <time_frame>1 month</time_frame>
    <description>Proportion of patients admitted to coronary care unit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients admitted to high dependency unit</measure>
    <time_frame>1 month</time_frame>
    <description>Proportion of patients admitted to high dependency unit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who die during hospitalization</measure>
    <time_frame>1 month</time_frame>
    <description>Proportion of patients who die during hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>White blood cell on admission</measure>
    <time_frame>1 day</time_frame>
    <description>White blood cell count in blood (x 10^9 cells/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet count upon admission</measure>
    <time_frame>1 day</time_frame>
    <description>Platelet count in blood (x 10^9 cells/L) upon admission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alanine aminotransferase upon admission</measure>
    <time_frame>1 day</time_frame>
    <description>The level of alanine aminotransferase in blood (U/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatinine on admission</measure>
    <time_frame>1 day</time_frame>
    <description>The level of creatinine in blood (umol/L) upon</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood culture result</measure>
    <time_frame>3 days</time_frame>
    <description>The result of blood culture</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sputum culture result</measure>
    <time_frame>3 days</time_frame>
    <description>The result of sputum culture</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with pneumonia</measure>
    <time_frame>1 month</time_frame>
    <description>Proportion of patients with pneumonia</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Respiratory Virus Infection</condition>
  <condition>Stroke</condition>
  <condition>Lung Disease</condition>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>Hospitalized - ACS</arm_group_label>
    <description>Hospitalized patients with acute coronary syndrome</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hospitalized - stroke</arm_group_label>
    <description>Hospitalized patients with stroke</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hospitalized - chronic lung disease</arm_group_label>
    <description>Hospitalized patients with exacerbation of chronic lung disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Outpatient</arm_group_label>
    <description>Outpatients</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Respiratory virus testing</intervention_name>
    <description>All patients will be tested for respiratory viruses</description>
    <arm_group_label>Hospitalized - ACS</arm_group_label>
    <arm_group_label>Hospitalized - chronic lung disease</arm_group_label>
    <arm_group_label>Hospitalized - stroke</arm_group_label>
    <arm_group_label>Outpatient</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Saliva specimens will be retained&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        1. Hospitalized patients with acute coronary syndrome, stroke or exacerbation of&#xD;
             underlying lung disease&#xD;
&#xD;
          2. Outpatients follow-up for chronic conditions&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria: (For hospitalized patients)&#xD;
&#xD;
          1. Admitted to the acute medical ward of Queen Mary Hospital via the accident and&#xD;
             emergency department&#xD;
&#xD;
          2. Aged 18 years or above&#xD;
&#xD;
          3. Hospitalized for less than 24 hours at the time of recruitment&#xD;
&#xD;
          4. Presented with exacerbation of underlying lung disease, acute coronary syndrome or&#xD;
             stroke&#xD;
&#xD;
          5. Competent and agree to provide written informed consent&#xD;
&#xD;
        Exclusion Criteria: (For hospitalized patients)&#xD;
&#xD;
          1. Admitted to any hospitals in the past 14 days&#xD;
&#xD;
          2. Respiratory virus testing performed in the past 14 days&#xD;
&#xD;
          3. Antiviral against respiratory virus given within the past 14 days&#xD;
&#xD;
          4. Not sufficient saliva&#xD;
&#xD;
        Inclusion Criteria: (For out-patients)&#xD;
&#xD;
          1. Aged 18 years or above&#xD;
&#xD;
          2. Follow-up at out-patient clinic or at the physiotherapy department of Queen Mary&#xD;
             Hospital&#xD;
&#xD;
          3. Competent and agree to provide written informed consent&#xD;
&#xD;
        Exclusion criteria: (For out-patients)&#xD;
&#xD;
          1. Admitted to any hospitals in the past 14 days&#xD;
&#xD;
          2. Respiratory virus testing performed in the past 14 days&#xD;
&#xD;
          3. Antiviral against respiratory virus given within the past 14 days&#xD;
&#xD;
          4. Onset of new respiratory or non-respiratory symptoms within the past 14 days&#xD;
&#xD;
          5. Not sufficient saliva&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kelvin To, MD</last_name>
    <phone>(852)-22552413</phone>
    <email>kelvinto@hku.hk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelvin To, MD</last_name>
      <email>kelvinto@hku.hk</email>
    </contact>
    <investigator>
      <last_name>Kelvin To, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <results_reference>
    <citation>Sellers SA, Hagan RS, Hayden FG, Fischer WA 2nd. The hidden burden of influenza: A review of the extra-pulmonary complications of influenza infection. Influenza Other Respir Viruses. 2017 Sep;11(5):372-393. doi: 10.1111/irv.12470.</citation>
    <PMID>28745014</PMID>
  </results_reference>
  <results_reference>
    <citation>To KK, Lau SK, Chan KH, Mok KY, Luk HK, Yip CC, Ma YK, Sinn LH, Lam SH, Ngai CW, Hung IF, Chan KH, Yuen KY. Pulmonary and extrapulmonary complications of human rhinovirus infection in critically ill patients. J Clin Virol. 2016 Apr;77:85-91. doi: 10.1016/j.jcv.2016.02.014. Epub 2016 Feb 20.</citation>
    <PMID>26921740</PMID>
  </results_reference>
  <results_reference>
    <citation>Warren-Gash C, Blackburn R, Whitaker H, McMenamin J, Hayward AC. Laboratory-confirmed respiratory infections as triggers for acute myocardial infarction and stroke: a self-controlled case series analysis of national linked datasets from Scotland. Eur Respir J. 2018 Mar 29;51(3):1701794. doi: 10.1183/13993003.01794-2017. Print 2018 Mar.</citation>
    <PMID>29563170</PMID>
  </results_reference>
  <results_reference>
    <citation>To KK, Lu L, Yip CC, Poon RW, Fung AM, Cheng A, Lui DH, Ho DT, Hung IF, Chan KH, Yuen KY. Additional molecular testing of saliva specimens improves the detection of respiratory viruses. Emerg Microbes Infect. 2017 Jun 7;6(6):e49. doi: 10.1038/emi.2017.35.</citation>
    <PMID>28588283</PMID>
  </results_reference>
  <results_reference>
    <citation>To KKW, Yip CCY, Lai CYW, Wong CKH, Ho DTY, Pang PKP, Ng ACK, Leung KH, Poon RWS, Chan KH, Cheng VCC, Hung IFN, Yuen KY. Saliva as a diagnostic specimen for testing respiratory virus by a point-of-care molecular assay: a diagnostic validity study. Clin Microbiol Infect. 2019 Mar;25(3):372-378. doi: 10.1016/j.cmi.2018.06.009. Epub 2018 Jun 12.</citation>
    <PMID>29906597</PMID>
  </results_reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>January 15, 2019</study_first_submitted>
  <study_first_submitted_qc>January 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 25, 2019</study_first_posted>
  <last_update_submitted>March 23, 2020</last_update_submitted>
  <last_update_submitted_qc>March 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Respiratory virus infection</keyword>
  <keyword>Extrapulmonary complications</keyword>
  <keyword>Myocardial infarction</keyword>
  <keyword>Asthma</keyword>
  <keyword>Bronchiectasis</keyword>
  <keyword>Chronic obstructive pulmonary disease</keyword>
  <keyword>Cerebrovascular disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 4, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/59/NCT03816059/ICF_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 4, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/59/NCT03816059/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03816059
org study id: 20190104
nct id: NCT03816059
lead sponsor: 
has dmc: No
is fda regulated drug: No
is fda regulated device: No
Respiratory virus infections are one of the major causes of hospitalizations, and outbreaks
      of respiratory virus infection have led to severe economic loss. In addition to pulmonary
      complications, respiratory viruses can also lead to non-pulmonary complications.

      However, many previous studies on the complications of respiratory viruses are retrospective
      in nature, and therefore many patients with respiratory virus infection may not be tested.
      Furthermore, these studies did not take into account that respiratory viruses can be found in
      some asymptomatic individuals. The aim of this study is to capture the burden of respiratory
      viruses in patients with acute pulmonary and extrapulmonary complications. We will recruit
      patients admitted to our hospital with acute coronary syndrome, stroke and exacerbation of
      underlying lung diseases. We will collect saliva from these patients and test for respiratory
      viruses. As controls, we will recruit asymptomatic patients at the out-patient clinic for
      follow up of chronic heart, lung or neurological diseases.

      We anticipate that this study will greatly enhance our understanding of the epidemiology of
      respiratory viruses in acutely hospitalized patients. Our findings will be important for
      clinicians, public health practitioners and scientists.
Respiratory viruses cause severe infections, and contribute to a substantial number of
      hospitalizations, admission to intensive care units and deaths. Many hospitalizations due to
      respiratory virus infection are related to pneumonia or exacerbation of chronic lung disease.
      In addition, many hospitalizations are related to extrapulmonary complications, such as acute
      coronary syndrome or stroke.

      Previous studies have reported the incidence of respiratory viruses among patients with
      pulmonary complications, or the association of respiratory viruses with acute coronary
      syndrome or stroke. However, there are several problems associated with these studies. First,
      many of these studies are retrospective in nature, and therefore testing was only performed
      in selected patients with respiratory symptoms. Hence, many patients without respiratory
      symptoms were not recruited. Second, respiratory virus can be detected in some asymptomatic
      individuals. Therefore, the presence of respiratory virus may be an incidental finding rather
      than the cause of the complication. Third, many studies only focus on a few respiratory
      viruses, especially on influenza virus.

      This study aims to address these issues. The investigators propose to conduct a prospective
      cohort study. The investigators will recruit hospitalized adult patients with exacerbation of
      underlying lung disease, acute coronary syndrome or stroke. As controls, the investigators
      will recruit outpatients follow-up for chronic heart disease, chronic lung disease or
      neurological conditions. The investigators will collect saliva from study participants and
      perform respiratory virus testing using a multiplex PCR panel. Previous studies have shown
      that there is a high concordance between results from respiratory virus testing on saliva and
      nasopharyngeal specimens. The investigators will also use a standardized questionnaire to
      collect information regarding symptoms.

      This study will provide accurate data on the epidemiology of respiratory viruses in pulmonary
      and extrapulmonary complications.These data are important for clinicians, public health
      practitioners and scientists.
observational model: Cohort
time perspective: Prospective
measure: Incidence of respiratory viruses
time frame: 2 days
description: Incidence of respiratory viruses
measure: Length of hospital stay
time frame: 1 month
description: Length of hospital stay
measure: Length of stay in general medical ward
time frame: 1 month
description: Length of stay in general medical ward
measure: Length of stay in high dependency unit
time frame: 1 month
description: Length of stay in high dependency unit
measure: Length of stay in intensive care unit
time frame: 1 month
description: Length of stay in intensive care unit
measure: Proportion of patients requiring oxygen supplementation
time frame: 1 month
description: Proportion of patients requiring oxygen supplementation
measure: Proportion of patients requiring positive pressure ventilation
time frame: 1 month
description: Proportion of patients requiring positive pressure ventilation
measure: Proportion of patients requiring intubation
time frame: 1 month
description: Proportion of patients requiring intubation
measure: Proportion of patients admitted to intensive care unit
time frame: 1 month
description: Proportion of patients admitted to intensive care unit
measure: Proportion of patients admitted to coronary care unit
time frame: 1 month
description: Proportion of patients admitted to coronary care unit
measure: Proportion of patients admitted to high dependency unit
time frame: 1 month
description: Proportion of patients admitted to high dependency unit
measure: Proportion of patients who die during hospitalization
time frame: 1 month
description: Proportion of patients who die during hospitalization
measure: White blood cell on admission
time frame: 1 day
description: White blood cell count in blood (x 10^9 cells/L)
measure: Platelet count upon admission
time frame: 1 day
description: Platelet count in blood (x 10^9 cells/L) upon admission
measure: Alanine aminotransferase upon admission
time frame: 1 day
description: The level of alanine aminotransferase in blood (U/L)
measure: Creatinine on admission
time frame: 1 day
description: The level of creatinine in blood (umol/L) upon
measure: Blood culture result
time frame: 3 days
description: The result of blood culture
measure: Sputum culture result
time frame: 3 days
description: The result of sputum culture
measure: Proportion of patients with pneumonia
time frame: 1 month
description: Proportion of patients with pneumonia
arm group label: Hospitalized - ACS
description: Hospitalized patients with acute coronary syndrome
arm group label: Hospitalized - stroke
description: Hospitalized patients with stroke
arm group label: Hospitalized - chronic lung disease
description: Hospitalized patients with exacerbation of chronic lung disease
arm group label: Outpatient
description: Outpatients
intervention type: Diagnostic Test
intervention name: Respiratory virus testing
description: All patients will be tested for respiratory viruses
arm group label: Hospitalized - ACS
arm group label: Hospitalized - chronic lung disease
arm group label: Hospitalized - stroke
arm group label: Outpatient
Saliva specimens will be retained
study pop: 
sampling method: Non-Probability Sample
criteria: 
gender: All
minimum age: 18 Years
maximum age: N/A
healthy volunteers: No
last name: Kelvin To, MD
phone: (852)-22552413
email: kelvinto@hku.hk
facility: 
status: Recruiting
contact: 
investigator: 
country: Hong Kong
citation: Sellers SA, Hagan RS, Hayden FG, Fischer WA 2nd. The hidden burden of influenza: A review of the extra-pulmonary complications of influenza infection. Influenza Other Respir Viruses. 2017 Sep;11(5):372-393. doi: 10.1111/irv.12470.
PMID: 28745014
citation: To KK, Lau SK, Chan KH, Mok KY, Luk HK, Yip CC, Ma YK, Sinn LH, Lam SH, Ngai CW, Hung IF, Chan KH, Yuen KY. Pulmonary and extrapulmonary complications of human rhinovirus infection in critically ill patients. J Clin Virol. 2016 Apr;77:85-91. doi: 10.1016/j.jcv.2016.02.014. Epub 2016 Feb 20.
PMID: 26921740
citation: Warren-Gash C, Blackburn R, Whitaker H, McMenamin J, Hayward AC. Laboratory-confirmed respiratory infections as triggers for acute myocardial infarction and stroke: a self-controlled case series analysis of national linked datasets from Scotland. Eur Respir J. 2018 Mar 29;51(3):1701794. doi: 10.1183/13993003.01794-2017. Print 2018 Mar.
PMID: 29563170
citation: To KK, Lu L, Yip CC, Poon RW, Fung AM, Cheng A, Lui DH, Ho DT, Hung IF, Chan KH, Yuen KY. Additional molecular testing of saliva specimens improves the detection of respiratory viruses. Emerg Microbes Infect. 2017 Jun 7;6(6):e49. doi: 10.1038/emi.2017.35.
PMID: 28588283
citation: To KKW, Yip CCY, Lai CYW, Wong CKH, Ho DTY, Pang PKP, Ng ACK, Leung KH, Poon RWS, Chan KH, Cheng VCC, Hung IFN, Yuen KY. Saliva as a diagnostic specimen for testing respiratory virus by a point-of-care molecular assay: a diagnostic validity study. Clin Microbiol Infect. 2019 Mar;25(3):372-378. doi: 10.1016/j.cmi.2018.06.009. Epub 2018 Jun 12.
PMID: 29906597
responsible party type: Sponsor
mesh term: Infections
mesh term: Communicable Diseases
mesh term: Virus Diseases
mesh term: Lung Diseases
mesh term: Acute Coronary Syndrome
sharing ipd: No
provided document: 
provided document: 